Methacrylate Stabilizer for Baclofen Lactam Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
4-amino-3-substituted butanoic acid derivatives like baclofen, gabapentin, and pregabalin are prone to intramolecular autocondensation, leading to stability issues and limited shelf life due to their susceptibility to lactam formation, which conventional stabilizers often exacerbate by improving compression-moldability and flow.
Innovation Solution
The use of well-known release rate-controlling polymers with a methacrylate component, such as methyl methacrylate copolymers, as stabilizers in pharmaceutical compositions to inhibit lactam formation and enhance the stability of these derivatives, particularly by intimately mixing the active ingredient with the stabilizer in a matrix formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional auxiliaries are used to improve compression-moldability and flow, then manufacturing properties are improved, but autocondensation reaction rates increase
Solution Approach 1:
The patent introduces a stabilizer as an intermediary substance that mediates between the active ingredient and the harmful effects of conventional auxiliaries. The stabilizer prevents autocondensation reactions while allowing the formulation to maintain good compression-moldability and flow properties, effectively decoupling the stability issue from the manufacturing properties.
Solution Approach 2:
The patent changes the chemical parameters of the formulation by introducing specific stabilizers that alter the reaction environment. This prevents the autocondensation reaction without affecting the physical properties needed for manufacturing, thus resolving the contradiction between ease of manufacture and stability.
2Ease of operation
If conventional auxiliaries are used to improve flow, then processing properties are improved, but autocondensation reaction rates increase
Solution Approach 1:
The stabilizer acts as a protective intermediary that allows conventional flow-improving auxiliaries to function without triggering autocondensation. It mediates the interaction between the active ingredient and the formulation environment, enabling good flow properties while maintaining stability.
Solution Approach 2:
The stabilizer serves as a sacrificial component that protects the active ingredient from degradation. It is present in the formulation specifically to prevent harmful reactions, allowing the use of other auxiliaries for processing improvement without compromising stability.
3Speed
If storage temperature is elevated, then reaction rate increases, but shelf life decreases
Solution Approach 1:
The stabilizer provides preliminary protection against autocondensation reactions before they can occur. By pre-establishing a protective environment in the formulation, it prevents the temperature-accelerated reaction from proceeding, thereby extending shelf life even when stored at elevated temperatures.
Solution Approach 2:
The stabilizer acts as a cushioning agent that absorbs or mitigates the harmful effects of elevated storage temperatures. It provides beforehand protection that slows down the autocondensation reaction rate despite temperature increases, thereby extending the shelf life of the pharmaceutical composition.
Data Source
AI summary
Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.